Enlivex Therapeutics Ltd.   Report issue

For profit Phase 1 Phase 2
Founded: Ness Ziona Israel (2005)

Organization Overview

First Clinical Trial
2019
NCT03925857
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Enlivex Therapeutics Ltd. | Enlivex Therapeutics LTD Email:mevorachd@gmail.com | Enlivex Therapeutics R&D | Enlivex Therapeutics RDO Ltd.

Active Ingredients

Drugs in Phase 2 Trials (2)

allocetra-ots (6 trials)

nivolumab (opdivo) (1 trial)

Drugs in Phase 1 Trials (1)

ringer's lactate (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Pneumonia (Phase 2)

Sepsis (Phase 2)

Systemic Inflammatory Response Syndrome (Phase 1)

Toxemia (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 6
  • # of Trial APIs: 3